German AMNOG reform fails to hit the mark
This article was originally published in SRA
Executive Summary
Reform of Germany's controversial early benefit assessments for new medicines is currently under discussion, but the changes floated look unlikely to solve any of the main issues that are frustrating pharmaceutical companies. During a recent debate in the German parliament, industry made little progress on ensuring that rebates remain confidential, and nothing is likely to change on the thorny issue of comparators, according to Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs and Brussels representative for the BPI, which represents small- and medium-sized companies in Germany.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.